Luxiq

   
Google
 
Web NewDrugInformation.com

Luxiq


Drug - Luxiq
The trade name of the product as shown on the labeling.

Dosage - AEROSOL, FOAM; TOPICAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Betamethasone Valerate
Multiple ingredients are in alphabetical order.

Strength - EQ 0.12% BASE
The potency of the active ingredient(s), Betamethasone Valerate. May repeat for multiple part products.

Applicant - CONNETICS
The firm name holding legal responsibility for Luxiq. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020934
The FDA assigned number to Luxiq. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Luxiq. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Feb 28, 1999
The date Luxiq was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Luxiq. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Luxiq is in. Format is RX, OTC, DISCN.

Applicant Full Name - Connetics Corp
The full name of the firm holding legal responsibility for the new application of Luxiq.

Luxiq